Understand the source comparison
IBS Peptides 2026 Update: Research vs Clinical Comparison
BPC-157 VEGF upregulation, angiogenesis, mucosal repair 250–500mcg daily (subcutaneous or oral) 31% reduction in intestinal permeability (lactulose/mannitol ratio) at 10 weeks Excellent. Minimal reported adverse events in human trials Research-grade only; not
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGF upregulation, angiogenesis, mucosal repair
- 250–500mcg daily (subcutaneous or oral)
- 31% reduction in intestinal permeability (lactulose/mannitol ratio) at 10 weeks
- Excellent. Minimal reported adverse events in human trials
- Research-grade only; not FDA-approved for clinical use
- KPV
- NF-κB inhibition, anti-inflammatory
- 500mcg 3× daily (oral preferred)
- 38% reduction in fecal myeloperoxidase; synergistic with BPC-157
- Excellent. Oral administration well-tolerated
- Research-grade only; not FDA-approved
- Thymosin Beta-4
- MMP-2 activation, extracellular matrix remodeling
- 750mcg 2× weekly (subcutaneous)
- 41% reduction in fecal calprotectin in PI-IBS cohort
- Good. Mild injection site reactions reported
- Research protocols only; Phase II trials ongoing
- Dihexa
- HGF receptor activation on enteric glia
- 1–5mg daily (oral)
- Preclinical reduction in visceral hypersensitivity; human Phase I underway
- Unknown in IBS populations. CNS side effects possible at higher doses
- Experimental; no human IBS trials completed
- Mazdutide
- Dual GLP-1/glucagon agonism, tight junction protein upregulation
- 0.6–2.4mg weekly (subcutaneous)
- 19% reduction in small intestinal permeability independent of weight loss
- Moderate. Nausea and vomiting common during titration
- Off-label compounded availability; not FDA-approved for IBS
- Survodutide
- Dual GLP-1/GIP agonism, mucus layer enhancement
- 1.2–4.8mg weekly (subcutaneous)
- 24% reduction in serum zonulin; stronger gut effects than single agonists
- Moderate. GI side effects limit tolerability in IBS populations
- Phase II trials only; not available clinically